Skip to main content
search
Video

Accelerating CMC Success in Rare Disease Drug Development

New drug approvals in rare diseases are rising, bringing hope to patients. But with accelerated regulatory pathways comes immense pressure on CMC teams to deliver high-quality products under tighter timelines. In our latest Expert Video Series, Deven Shah, 𝗛𝗲𝗮𝗱 𝗼𝗳 𝗖𝗠𝗖 𝗮𝘁 𝗖𝗲𝗿𝘁𝗮𝗿𝗮, shares his perspective on overcoming key challenges—navigating diverse modalities, managing agile manufacturing, and leveraging in silico modeling to optimize formulation and supply strategies.

You May Also Like

Rare Oncology Product Launch Playbook: Universal Strategies for Success in the U.S. and Europe
Rare Oncology Product Launch Playbook: Universal Strategies for Success in the U.S. and EuropeWhite Paper

Rare Oncology Product Launch Playbook: Universal Strategies for Success in the U.S. and Europe

Leveraging Real-World Evidence (RWE) in Rare Disease Drug Development
Leveraging Real-World Evidence (RWE) in Rare Disease Drug DevelopmentVideo

Leveraging Real-World Evidence (RWE) in Rare Disease Drug Development

Bridging Global Health Disparities in Rare Disease Drug Development
Bridging Global Health Disparities in Rare Disease Drug DevelopmentVideo

Bridging Global Health Disparities in Rare Disease Drug Development